Loading clinical trials...
Loading clinical trials...
A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA
Conditions
Interventions
glasdegib
daunorubicin + cytarabine
+6 more
Locations
149
United States
UCLA Department of Medicine
Los Angeles, California, United States
UCLA Drug Information/Investigational Drugs
Los Angeles, California, United States
UCLA Hematology/Oncology Clinic
Los Angeles, California, United States
UCLA Ronald Reagan Medical Center
Los Angeles, California, United States
UC Irvine Health - Chao Family Comprehensive Cancer Center
Orange, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Start Date
April 20, 2018
Primary Completion Date
June 5, 2020
Completion Date
January 17, 2022
Last Updated
April 21, 2023
NCT07216443
NCT06852222
NCT06580106
NCT06501196
NCT06384261
NCT06382168
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions